This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Nogapendekin alfa inbakicept — Description, Dosage, Side Effects | PillsCard
OTC
Nogapendekin alfa inbakicept
400 mcg, Koncentrat do sporządzania zawiesiny do wstrzykiwań
INN: Nogapendekin alfa inbakicept
Data updated: 2026-04-13
Available in:
🇨🇿🇬🇧🇵🇱
Form
Koncentrat do sporządzania zawiesiny do wstrzykiwań
Dosage
400 mcg
Route
do pęcherza moczowego
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
ImmunityBio Ireland Limited (Holandia)
Composition
Nogapendekin alfa inbakicept 400 mcg
ATC Code
L03AC03
Source
URPL
USDailyMed:Nogapendekin alfa inbakicept
L03AC03(WHO)
US:℞-only
497621301
D12888
Nogapendekin alfa inbakicept, sold under the brand nameAnktiva, is afixed-dose combination medicationused for the treatment ofbladder cancer.It is aninterleukin-15 receptoragonist.It is given in combination withBacillusCalmette-Guérin (BCG) viaintravesical drug delivery.It containsnogapendekin alfa, a human IL-15(N72D) variant, which is more potent than regular IL-15;andinbakicept, an interleukin 15 receptor subunit alpha agonist.
The most common adverse reactions include increasedcreatinine,dysuria,hematuria, urinary frequency,micturitionurgency,urinary tract infection, increased potassium, musculoskeletal pain, chills, andpyrexia.
Nogapendekin alfa inbakicept was approved for medical use in the United States in April 2024.The USFood and Drug Administrationconsiders it to be afirst-in-class medication.
PillsCard reference image